- Trials with a EudraCT protocol (72)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (5)
72 result(s) found for: Channel blockers.
Displaying page 1 of 4.
EudraCT Number: 2015-001761-11 | Sponsor Protocol Number: 300488 | Start Date*: 2015-08-31 | ||||||||||||||||
Sponsor Name:The Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital | ||||||||||||||||||
Full Title: Lymphatic dysfunction as a cause of calcium channel blocker oedema in post-menopausal women | ||||||||||||||||||
Medical condition: Calcium channel antagonist induced peripheral edema in post-menopausal women. We hypothesize that this condition is partly due to impaired lymphatic function in these patients. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000605-12 | Sponsor Protocol Number: notapplicable1 | Start Date*: 2014-06-13 |
Sponsor Name: | ||
Full Title: Thiazide diuretics versus calcium channel blockers for the treatment of calcineurin inhibitor-induced hypertension in patients with psoriasis or eczema: a single-center randomized cross-over trial. | ||
Medical condition: Hypertension, induced by the use of a Calcineurin Inhibitor (CNI) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-004704-35 | Sponsor Protocol Number: NL39417.078.12 | Start Date*: 2012-11-22 |
Sponsor Name: | ||
Full Title: Thiazide diuretics versus calcium channel blockers for the treatment of tacrolimus-induced hypertension in dermatology patients: a single-center randomized cross-over trial. | ||
Medical condition: Hypertension, induced by the use of a Calcineurin Inhibitor (CNI) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004192-37 | Sponsor Protocol Number: CRO1749 | Start Date*: 2012-04-24 | |||||||||||
Sponsor Name:Joint Research Compliance Office, Imperial College | |||||||||||||
Full Title: Hellenic Anglo Research into Morning Or Night antihypertensive drug deliverY trial. | |||||||||||||
Medical condition: Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004288-47 | Sponsor Protocol Number: ERA-2005-bachmg | Start Date*: 2005-10-04 |
Sponsor Name:Hôpital Erasme | ||
Full Title: Etude des effets d'un antagoniste calcique(la barnidipine) sur la sensibilité des chémorécepteurs et l'activité orthosympathique. | ||
Medical condition: 2 groups of patients: one group of patients with systemic hypertension and one another group with control subjects free of disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-001187-33 | Sponsor Protocol Number: APD811-301 | Start Date*: 2019-02-12 | |||||||||||
Sponsor Name:Arena Pharmaceuticals, Inc. | |||||||||||||
Full Title: A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients | |||||||||||||
Medical condition: pulmonary arterial hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Completed) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001250-91 | Sponsor Protocol Number: GV-002.001 | Start Date*: 2005-10-04 |
Sponsor Name:GenVec, Inc. | ||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of BIOBYPASS® (ADGVVEGF121.10NH) Delivered by NOGA-Guided/MYOSTAR Catheter in "No Option" Patients with Cla... | ||
Medical condition: Moderate to severe angina pectoris due to advanced coronary artery disease (CAD). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) AT (Completed) DE (Completed) GB (Completed) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003998-27 | Sponsor Protocol Number: RD-5103-003-06 | Start Date*: 2007-03-15 |
Sponsor Name:Derby Hospitals NHS Foundation Trust | ||
Full Title: Cardiovascular and functional consquences of chronic kidney disease in older people | ||
Medical condition: Chronic Kidney Disease Hypertension Falls | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004060-40 | Sponsor Protocol Number: AGO15 | Start Date*: 2008-03-13 |
Sponsor Name:Studienzentrale AGO Austria | ||
Full Title: Phase II multicenter trial of the Austrian AGO of the combination of liposomal Doxorubicin (Myocet®) and Carboplatin in primary advanced or metastatic and recurrent endometrial cancer | ||
Medical condition: primary advanced or recurrent/metastatic endometrial cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-003839-20 | Sponsor Protocol Number: CVT5127 | Start Date*: 2009-02-24 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Open-Label, Parallel-Group, Exploratory Study to Evaluate the Efficacy and Safety of 400 µg Regadenoson Bolus for Pharmacological Stress Echocardiography | |||||||||||||
Medical condition: Suspected coronary artery disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001793-21 | Sponsor Protocol Number: CPA12001 | Start Date*: 2013-08-06 | |||||||||||
Sponsor Name:PHARMATHEN S.A. | |||||||||||||
Full Title: Efficacy and tolerability of brinzolamide in patients with elevated intraocular pressure: a double-blind, randomized, parallel, verum-controlled trial. | |||||||||||||
Medical condition: intraocular pressure increased | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002516-33 | Sponsor Protocol Number: NCT01420393 | Start Date*: 2015-09-03 |
Sponsor Name:University of Ottawa Heart Institute | ||
Full Title: A Randomized Ablation-based atrial Fibrillation rhythm control versus rate control Trial in patients with heart failure and high burden Atrial Fibrillation | ||
Medical condition: The study is comparing two accepted treatment methods (rhythm control-Catheter ablation with or without anti-arrhythmic drug control of maintaining sinus rhythm versus rate controls with medical th... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019009-40 | Sponsor Protocol Number: A7331010 | Start Date*: 2010-07-08 | |||||||||||
Sponsor Name:Pfizer, S.A. | |||||||||||||
Full Title: Estudio clínico de Fase 2A, multicéntrico aleatorizado, doble ciego, controlado con placebo y con un fármaco activo, de diseño cruzado con dos cohortes y dos dosis, para la evaluación de la eficaci... | |||||||||||||
Medical condition: Tratamiento del vasospasmo en el fenómeno de Raynaud primario y secundario. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SE (Completed) CZ (Completed) DE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005887-14 | Sponsor Protocol Number: B1321003 | Start Date*: 2010-01-12 | |||||||||||
Sponsor Name:Pfizer Ltd. | |||||||||||||
Full Title: A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF MONOTHERAPY SITAXSENTAN SODIUM VERSUS COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS ... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000500-26 | Sponsor Protocol Number: 01-1-101 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Rapidscan Pharma Solutions EU Ltd (RPS EU Ltd) | |||||||||||||
Full Title: An Open-label, Single Ascending-dose, Pharmacokinetic and Safety Study of Regadenoson (Rapidscan®) in Paediatric Patients with Cardiovascular Conditions and Diseases | |||||||||||||
Medical condition: Regadenoson will be used as a pharmacologic stress agent in paediatric patients with cardiovascular problems, undergoing a clinically indicated myocardial perfusion MRI | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001674-25 | Sponsor Protocol Number: 1684-H-295 | Start Date*: 2012-05-25 | |||||||||||
Sponsor Name:Francisco J. González Vílchez | |||||||||||||
Full Title: Evaluation of the efficacy of sildenafil on the functional capacity of patients with heart failure with preserved ejection fraction. A randomized, double blind, parallel group and placebo-controlle... | |||||||||||||
Medical condition: Heart failure with preserved ejection fraction. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001936-23 | Sponsor Protocol Number: BRAKE-AF | Start Date*: 2018-09-21 | |||||||||||
Sponsor Name:Dr. Adolfo Fontenla Cerezuela | |||||||||||||
Full Title: A multicenter, randomized, open-label, phase III clinical trial to compare the efficacy and safety of Ivabradine versus Digoxine in the chronic control of heart rate in patients with permanent atri... | |||||||||||||
Medical condition: Heart rate control in patients with chronic atrial fibrillation. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000331-16 | Sponsor Protocol Number: C-935788-050 | Start Date*: 2014-07-28 |
Sponsor Name:Rigel Pharmaceuticals Inc | ||
Full Title: A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy | ||
Medical condition: IgA nephropathy (IgAN) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-017155-10 | Sponsor Protocol Number: 10-aifa-2005-01 | Start Date*: 2006-11-07 | |||||||||||
Sponsor Name:CASA DI CURA PRIVATA S.RAFFAELE - PISANA | |||||||||||||
Full Title: Evaluation of tolerability and efficacy of the combination Sildenafil/Bosentan in patients with severe pulmonary hypertension. | |||||||||||||
Medical condition: severe pulmonary hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000397-23 | Sponsor Protocol Number: SLx-2101-07-04 | Start Date*: 2007-05-29 | |||||||||||
Sponsor Name:Surface Logix, Inc. | |||||||||||||
Full Title: A randomised, double blind, placebo-controlled, cross-over pilot study to examine the safety, tolerability and pharmacodynamic profile of repeat oral doses of SLx-2101 once daily for up to 14 days ... | |||||||||||||
Medical condition: Raynaud's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
